406 related articles for article (PubMed ID: 18020980)
1. Selective Raf inhibition in cancer therapy.
Khazak V; Astsaturov I; Serebriiskii IG; Golemis EA
Expert Opin Ther Targets; 2007 Dec; 11(12):1587-609. PubMed ID: 18020980
[TBL] [Abstract][Full Text] [Related]
2. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
3. Targeting Raf-kinase: molecular rationales and translational issues.
Caraglia M; Tassone P; Marra M; Budillon A; Venuta S; Tagliaferri P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii124-7. PubMed ID: 16760274
[TBL] [Abstract][Full Text] [Related]
4. A patent review of RAF kinase inhibitors (2010-2018).
Man RJ; Zhang YL; Jiang AQ; Zhu HL
Expert Opin Ther Pat; 2019 Sep; 29(9):675-688. PubMed ID: 31370713
[No Abstract] [Full Text] [Related]
5. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
6. The non-linearity of RAF-MEK signaling in dendritic cells.
Riegel K; Rajalingam K
Cell Cycle; 2020 Sep; 19(18):2249-2259. PubMed ID: 32752922
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the research and development of RAF kinase inhibitors.
Smith RA; Dumas J; Adnane L; Wilhelm SM
Curr Top Med Chem; 2006; 6(11):1071-89. PubMed ID: 16842147
[TBL] [Abstract][Full Text] [Related]
8. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
Kim DH; Sim T
Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
[TBL] [Abstract][Full Text] [Related]
9. Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Ammar UM; Abdel-Maksoud MS; Oh CH
Eur J Med Chem; 2018 Oct; 158():144-166. PubMed ID: 30216849
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract][Full Text] [Related]
11. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U; Wang M; Hu J
Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
[TBL] [Abstract][Full Text] [Related]
12. Raf kinases: oncogenesis and drug discovery.
Schreck R; Rapp UR
Int J Cancer; 2006 Nov; 119(10):2261-71. PubMed ID: 16894562
[TBL] [Abstract][Full Text] [Related]
13. RAS/RAF/MEK inhibitors in oncology.
Rusconi P; Caiola E; Broggini M
Curr Med Chem; 2012; 19(8):1164-76. PubMed ID: 22257058
[TBL] [Abstract][Full Text] [Related]
14. INN common stem: -rafenib.
Prescrire Int; 2015 Apr; 24(159):91. PubMed ID: 25941726
[No Abstract] [Full Text] [Related]
15. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
16. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
18. Targeting Alterations in the RAF-MEK Pathway.
Yaeger R; Corcoran RB
Cancer Discov; 2019 Mar; 9(3):329-341. PubMed ID: 30770389
[TBL] [Abstract][Full Text] [Related]
19. Development of small-molecule inhibitors of Raf.
Wu S; Guo W; Fang B
Recent Pat Antiinfect Drug Discov; 2006 Jun; 1(2):241-6. PubMed ID: 18221149
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.
Lee JT; McCubrey JA
Expert Opin Ther Targets; 2002 Dec; 6(6):659-78. PubMed ID: 12472379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
